{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:11:20Z","timestamp":1777911080314,"version":"3.51.4"},"reference-count":30,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2016]]},"DOI":"10.7883\/yoken.jjid.2015.023","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T22:05:18Z","timestamp":1436479518000},"page":"113-117","source":"Crossref","is-referenced-by-count":12,"title":["In Vivo Efficacy of Drugs against &lt;i&gt;Toxoplasma gondii&lt;\/i&gt; Combined with Immunomodulators"],"prefix":"10.7883","volume":"69","author":[{"given":"Zeynep \u015eent&uuml;rk","family":"K&ouml;ksal","sequence":"first","affiliation":[{"name":"Microbiology Laboratory, Gazi State Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keramettin","family":"Yanik","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Medical Faculty"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"Bilgin","sequence":"additional","affiliation":[{"name":"Department of Medical Services and Techniques, Vocational School of Health Services, Ondokuz Mayis University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esmeray Mutlu","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Samsun Training and Research Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Hokelek","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Istanbul University Cerrahpasha Medical Faculty"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4631","reference":[{"key":"1","unstructured":"1. Altinta&#x15F; N, Kuman HA, Akisu C, et al. Toxoplasmosis in last four years in Ageon region, Turkey. J Egypt Soc Parsitol. 1997;27:439-43."},{"key":"2","unstructured":"2. G&uuml;r&uuml;z AY, &Ouml;zcel MA. Toxoplasmosis. In: &Ouml;zcel MA, editor. Medical Parasitic Diseases. Izmir, Turkey: Turkish Society for Parasitology Press; 2007. p. 141-189. Turkish."},{"key":"3","unstructured":"3. Rosenthal PJ, Goldsmith RS. Protozoal and helminthic infections. In: Trierney LM, Papadakis MA, McPhee SJ, editors. Current Medical Diagnosis &amp; Treatment. Lange Medical Books, 40th edition. New York, NY: McGraw-Hill Education; 2001. p. 1444-1447."},{"key":"4","unstructured":"4. Ajioka, JW, Soldati D. Preface. In: Ajioka JW, Soldati D, editors. <i>Toxoplasma<\/i>. Molecular and Cellular Biology. Norfolk, VA: Horizon Bioscience Scientific Press; 2007. p. 3-8."},{"key":"5","unstructured":"5. T&ouml;re O. Toxoplasmosis. In: Top&ccedil;u AW, Soyletir G, Doganay M, editors. Infectious Diseases. Istanbul, Turkey: Nobel T&#x131;p Kitabevleri; 1996. p. 525-532. Turkish."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet. 1999;353:1834-7.","DOI":"10.1016\/S0140-6736(98)11281-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med. 2007;12:214-23.","DOI":"10.1016\/j.siny.2007.01.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Araujo FG, Khan AA, Remington JS. Rifapentine is active in vitro and in vivo against <i>Toxoplasma gondii<\/i>. Antimicrob Agents Chemother. 1996;40:1335-7.","DOI":"10.1128\/AAC.40.6.1335"},{"key":"9","unstructured":"9. Montoya JG, Remington JS. <i>Toxoplasma gondii<\/i>. In: Mandell GL, Bennett JE, Dolin R editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, Philadelphia, PA: Elsevier; 2008. p. 2858-2888."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Pfefferkorn ER, Borotz SE. Comparison of mutants of <i>Toxoplasma gondii<\/i> selected for resistant to azithromycin, spiramycin, or clindamycin. Antimicrob Agents Chemother. 1994;38:31-7.","DOI":"10.1128\/AAC.38.1.31"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Reynolds MG, Oh J, Roos DS. In vitro generation of novel pyrimethamine resistance mutations in the <i>Toxoplasma gondii<\/i> dihydrofolate reductase. Antimicrob Agents Chemother. 2001;45:1271-7.","DOI":"10.1128\/AAC.45.4.1271-1277.2001"},{"key":"12","unstructured":"12. Bauer VR, Jurcic K, Puhlmann J, et al. Immunologic in vivo and in vitro studies on <i>Echinacea<\/i> extracts. Arzneimittelforschung. 1988;38:276-81."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Luettig B, Steinmuller C, Gifford GE, et al. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of <i>Echinacea purpurea<\/i>. J Natl Cancer Inst. 1989;81:669-75.","DOI":"10.1093\/jnci\/81.9.669"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Stevenson LM, Matthias A, Banbury L, et al. Modulation of macrophage immune responses by Echinacea. Molecules. 2005;10:1279-85.","DOI":"10.3390\/10101279"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sullivan AM, Laba JG, Moore JA, et al. <i>Echinacea<\/i>-induced macrophage activation. Immunopharmacol Immunotoxicol. 2008;30:553-74.","DOI":"10.1080\/08923970802135534"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhai Z, Liu Y, Wu L, et al. Enhancement of innate and adaptive immune functions by multiple <i>Echinacea<\/i> species. J Med Food. 2007;10:423-34.","DOI":"10.1089\/jmf.2006.257"},{"key":"17","unstructured":"17. Ri&#x15F;vanl&#x131; A, Ayd&#x131;n M. The effects of levamisole on the pregnancy rate, avarage litter size, sexuality, living rate and lactation period in rats. F&#x131;rat University Medical Journal of Health. 2003;17:45-7. Turkish."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Brunner CJ, Muscoplat CC. Immunomodulatory effects of levamisole. J Am Vet Med Assoc. 1980;176:1159-62.","DOI":"10.2460\/javma.1980.176.10.1159"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kimball ES, Clark MC, Schneider CR, et al. Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole. Clin Immunol Immunopathol. 1991;58:385-98.","DOI":"10.1016\/0090-1229(91)90129-X"},{"key":"20","unstructured":"20. &#304;spir &Uuml;, D&ouml;r&uuml;c&uuml; MA. Study on the effects of levamisole on the immune system of rainbow trout (<i>Oncorhynchus mykiss<\/i>, Walbaum). Turk J Vet Anim. 2005;29:1169-76."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Khan AA, Slifer T, Araujo FG, et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. Antimicrob Agents Chemother. 1997;41:893-7.","DOI":"10.1128\/AAC.41.5.893"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Khan AA, Slifer TR, Araujo FG, et al. Activity of gatifloxacin alone or in combination with pyrimethamine or gamma interferon against <i>Toxoplasma gondii<\/i>. Antimicrob Agents Chemother. 2001;45:48-51.","DOI":"10.1128\/AAC.45.1.48-51.2001"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Romand S, Bryskier A, Moutot M, et al. In vitro and in vivo activities of roxithromycin in combination with pyrimethamine or sulfadiazine against <i>Toxoplasma gondii<\/i>. J Antimicrob Chemother. 1995;35:821-32.","DOI":"10.1093\/jac\/35.6.823"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Araujo FG, Prokocimer P, Lin T, et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother. 1992;36:2454-7.","DOI":"10.1128\/AAC.36.11.2454"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Derouin F, Almadany R, Chau F, et al. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother. 1992;36:997-1001.","DOI":"10.1128\/AAC.36.5.997"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against <i>Toxoplasma gondii<\/i>. Antimicrob Agents Chemother. 1993;37:2371-8.","DOI":"10.1128\/AAC.37.11.2371"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ferreira RA, Oliveira AB, Ribeiro MF, et al. <i>Toxoplasma gondii<\/i>: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. Exp Parasitol. 2006;113:125-9.","DOI":"10.1016\/j.exppara.2005.12.006"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Khan AA, Nasr M, Araujo FG. Two 2-hydroxy-3-alkyl-1,4-naphthoquinones with in vitro and in vivo activities against <i>Toxoplasma gondii<\/i>. Antimicrob Agents Chemother. 1998;42:2284-9.","DOI":"10.1128\/AAC.42.9.2284"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Berkner D, Sioris L. <i>Echinacea<\/i> herbal products. In: Tracey TS, Kingston RL, editors. Herbal Products: Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press; 2007. p.97-109.","DOI":"10.1007\/978-1-59745-383-7_6"},{"key":"30","unstructured":"30. Kayaalp O. Antiamoebic drugs and other antiprotozoal drugs. In: Kayaalp O, editor. Rational Treatment Aspect of Medical Pharmacology. 12th edition. Ankara, Turkey. Pelikan Press; 2009. p. 344-354. Turkish."}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/69\/2\/69_JJID.2015.023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T03:27:49Z","timestamp":1748489269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/69\/2\/69_JJID.2015.023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2015.023","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}